Patients with inflammatory bowel disease, which involves an autoimmunity-associated PTPN22 variant, exhibit increased IL-1β levels, underscoring the role of Y861 phosphorylation in regulating NLRP3 and preventing aberrant inflammasome activation [150]. Here, NLRP3 is linked to inflammatory bowel disease.